Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna Mohs Micrographic Surgery Coverage Update | …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0383

    Mohs Micrographic Surgery

    Customize your policy alerts

    Sign up for Aetna Policy 0383 alerts

    Get alerted when Policy 0383 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the medical necessity, coverage, and coding for Mohs micrographic surgery (MMS) for treatment of specified skin cancers and related conditions for Aetna members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyMohs Micrographic Surgery
    Policy CodePolicy 0383
    Change TypeNo material change
    Effective DateFeb 1, 2000
    Last ReviewJun 22, 2023
    Next Review DateApr 11, 2024
    Key ActionDocument clinical justification and supporting tumor characteristics when requesting prior authorization to demonstrate the lesion meets listed medical necessity indications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12specific indications listed
    17311-17315covered CPTs
    0470T-0471TOCT codes not covered
    Q4100-Q4255skin substitute codes investigational
    06/22/2023last review
    02/01/2000policy effective

    Coverage Criteria and Evidence Summary

    Medical Necessity

    Covered when ANY of the following are met:

    MMS medical necessity indications: 1) Lesions in areas of important tissue preservation (ears, face, feet, hands, genitalia, perianal); 2) Atypical fibroxanthoma; 3) Dermatofibrosarcoma protuberans; 4) Exceptionally large (>= 2 cm) or rapidly growing lesions in any anatomic region; 5) Lesions in anatomic areas with high risk of recurrence (e.g., face — especially around eyes, mouth, nose, and central third, external ear and tragus, mucosal lesions, nail bed, periungual areas, scalp, temple); 6) Previously irradiated skin areas in any anatomic region; 7) Recurrent or incompletely excised malignant lesions; 8) Sebaceous carcinoma of highly sensitive areas (e.g., head and neck including eyelids); 9) Squamous cell carcinomas with high metastatic risk (including adenoid type, Bowen's disease, chronic osteomyelitis/sinuses/ulcers, discoid lupus erythematosus, lichen sclerosis et atrophicus, thermal or radiation injury); 10) Superficial malignant melanoma (in situ melanoma and lentigo maligna) in areas of important tissue preservation; 11) Tumors with aggressive histologic patterns (e.g., BCC morpheaform/sclerosing, basosquamous/metatypical, infiltrating, perineural/perivascular involvement, multicentric/contiguous tumors, poorly differentiated SCCs including adenoid/acantholytic/adenosquamous/desmoplastic/infiltrative variants); 12) Tumors with ill-defined borders.

    Policy lists these as separate OR-connected indications for MMS coverage.

    Experimental / Investigational (Not Covered)

    Experimental or investigational procedures: 1) Mohs micrographic surgery for all other indications not listed in the Medical Necessity section (e.g., deep cutaneous fungal infections); 2) Use of optical coherence tomography (OCT) for margin definition of basal cell carcinoma before Mohs micrographic surgery; 3) Skin substitutes for the management of Mohs micrographic surgery wounds; 4) Mohs micrographic surgery for the treatment of vulvar malignancies.

    These approaches are considered experimental/investigational and not covered.

    Evidence-based coverage considerations by tumor type

    Clinical evidence summarized in the document supports MMS as an effective option in certain tumor types and an alternative to WLE in others. Coverage considerations should reflect tumor-specific evidence:

    Extra‑mammary Paget disease (EMPD): Systematic review/meta-analysis (8 studies, 81 patients, 90 cases) showed MMS associated with lower recurrence rate vs wide local excision (odds ratio 0.20; 95% CI: 0.05–0.81) and an estimated 5-year tumor-free rate of ~83.6%.

    Evidence limited by small, nonrandomized studies; supports MMS effectiveness for EMPD.

    Lentigo maligna (LM): Retrospective cohort (423 lesions) reported lower recurrence for MMS (1.9%) versus WLE (5.9%) though the study was non-randomized and groups differed in lesion selection; both approaches had excellent outcomes.

    MMS often used for larger head/neck lesions with indistinct margins.

    Merkel cell carcinoma (MCC): NCDB retrospective review of early-stage MCC (1,795 cases) found no difference in overall survival or margin positivity between MMS and WLE, suggesting MMS is a reasonable tissue-sparing option for selected early-stage cases.

    Optimal approach remains undetermined; evidence from observational data only.

    Evidence summaries informing appropriate use

    Clinical evidence and guideline statements summarized in this section inform when MMS may be appropriate:

    Eyelid sebaceous carcinoma: Multi-center cohort (360 patients) found MMS associated with significantly lower local recurrence versus WLE (HR=0.42; 95% CI: 0.24–0.73; p=0.002) while metastasis and tumor-related mortality were comparable; UpToDate also supports WLE with frozen section or MMS as first-line for head and neck sebaceous carcinoma.

    MMS proposed for eyelid SC without orbital involvement to achieve recurrence control; pagetoid intraepithelial disease may need adjuvant therapy.

    Guideline/secondary source support: UpToDate states that WLE with frozen section margin control or, if available, MMS is first-line treatment for sebaceous carcinoma of the head and neck region, including eyelid tumors.

    UpToDate (Tai, 2019)

    Pediatrics: Systematic reviews report low recurrence and low complication rates for pediatric MMS cases but data are limited and challenges (anesthesia, cooperation, lab access) exist; further research needed.

    Wang et al 2020; Zargham & Khachemoune 2021.

    The policy identifies several specific procedures and applications that are excluded as experimental or investigational. These include: 1) Mohs micrographic surgery for indications not listed in the medical necessity section (for example, deep cutaneous fungal infections); 2) use of optical coherence tomography (OCT) for preoperative margin definition of basal cell carcinoma; and 3) use of skin substitutes for management of Mohs surgery wounds. The policy also explicitly lists Mohs micrographic surgery for vulvar malignancies as investigational and not covered under this section.

    The document highlights evidence limitations for certain indications: specifically, a Cochrane review found no randomized controlled trials comparing Mohs micrographic surgery versus surgical excision for peri‑ocular basal cell carcinoma, and therefore concluded that reliable comparative conclusions cannot be drawn. This absence of high‑quality RCT data may prompt additional clinical justification or review when MMS is requested for peri‑ocular BCC.

    Although some case series and systematic reviews report use of MMS for selected vulvar cutaneous malignancies, the policy notes that the NCCN clinical practice guideline on vulvar cancer (Version 1.2023) does not list Mohs micrographic surgery as a management option, and recommends that more robust studies are needed before routine adoption for these tumors.

    This Clinical Policy Bulletin is provided to assist in administering plan benefits and does not constitute a contract or an offer of coverage. Participating providers are independent contractors, and treating providers remain solely responsible for medical advice and treatment of members. Policy content may be updated and is subject to change.

    Procedures and technologies identified in the policy as experimental or investigational are not considered medically necessary for the indications listed. Examples called out include Mohs for indications not specifically enumerated in the medical‑necessity criteria (e.g., deep cutaneous fungal infections), preoperative margin mapping with OCT (CPT 0470T, 0471T), and the routine use of skin substitutes for MMS wounds. Claims for these services for the CPB indications may be denied.

    The policy summarizes evidence on high‑resolution ultrasound for preoperative assessment and reports that one study (100 patients) found a sensitivity of 32% and specificity of 88% for detecting tumor extension beyond clinically marked margins. Given the low sensitivity, high‑resolution ultrasound alone is not considered sufficiently reliable to replace standard intraoperative margin assessment for MMS planning.

    Within the provided excerpt, explicit phrases declaring services as “not medically necessary” are not present for every item; however, the policy does state that procedures listed in the Experimental and Investigational section (including OCT for margin definition and skin substitutes for MMS wounds) are considered investigational and therefore are not supported as medically necessary for the listed indications.

    CPT, HCPCS and ICD-10 Coding

    Covered CPT Codes (when selection criteria met)CPTCovered
    17311Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks.
    17312Each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure).
    17313Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks.
    17314Each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure).
    17315Each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure).
    88331Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen.
    88332Each additional tissue block with frozen section(s) (list separately in addition to code for primary procedure).
    CPT Codes Not Covered for Indications in CPBCPTNot Covered
    0470TOptical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; first lesion.
    0471TOptical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; each additional lesion (List separately in addition to code for primary procedure).
    Related HCPCS/CPT Skin Substitute Codes (investigational for MMS wounds)mixed
    15271-15278Application of skin substitute graft.
    A4100Skin substitute, fda cleared as a device, not otherwise specified.
    C1849Skin substitute, synthetic, resorbable, per square centimeter.
    C5271-C5278Application of low-cost skin substitute graft.
    C9363Skin substitute, integra meshed bilayer wound matrix, per square centimeter.
    Q4100-Q4255Skin substitutes.
    Covered ICD-10 Codes (when selection criteria met)ICD-10Covered
    C00.0-C00.9Malignant neoplasm of lip.
    C43.0-C43.9Malignant melanoma of skin.
    C44.*Multiple C44 diagnosis codes listed for BCC, SCC, sebaceous carcinoma and related sites (extensive ranges cited).
    D04.0-D04.9Carcinoma in situ of skin (Bowen's disease).
    D48.5Neoplasm of uncertain behavior of skin (DFSP, atypical fibroxanthoma).
    C60.0-C63.9Malignant neoplasm of male genital organs (penis and other male genital organs).
    ICD-10 Codes Not Covered for Indications in CPBICD-10Not Covered
    B35.0-B35.9Dermatophytosis.
    B36.0-B36.9Other superficial mycoses.
    B37.2Candidiasis of skin and nail.
    C51.0-C51.9Malignant neoplasm of vulva (not covered for MMS).
    D07.1-D07.39Carcinoma in situ of vulva and other and unspecified female genital organs (not covered for MMS).
    No explicit codes in this document segmentmixed
    No codes listed
    Lesion size threshold
    Lesion size threshold>= 2 cm in diameter (exceptionally large lesions listed as an indication)
    ContextListed as an independent indication for MMS when lesions are exceptionally large or rapidly growing
    Documentation implicationClinical documentation should record measured lesion diameter to support medical necessity

    Provider Guidance, Authorization, and Documentation

    Prior Authorization

    Coverage depends on meeting listed selection criteria

    Mohs CPT codes (17311–17315) and associated pathology codes (88331–88332) are covered only when the treated lesion meets one of the policy’s listed medical‑necessity indications (e.g., locations requiring tissue preservation, recurrent or aggressive histology, previously irradiated skin, DFSP, atypical fibroxanthoma, lesions ≥2 cm, etc.). Prior authorization may be required per payer rules.

    • Covered CPTs when selection criteria are met: 17311, 17312, 17313, 17314, 17315
    • Associated pathology codes: 88331, 88332
    • Medical‑necessity indications referenced in policy Sections I and II
    Prior Authorization

    Provide clinical justification for select tumor types

    When MMS is used for sebaceous carcinoma, eyelid tumors, or Merkel cell carcinoma, prior authorization requests should include clinical justification referencing tumor characteristics, intended tissue‑sparing benefit, and tumor‑specific evidence because the literature shows differing recurrence and survival outcomes by tumor type.

    Background and Context

    Mohs micrographic surgery (MMS) is a tissue‑sparing surgical technique in which the tumor is removed in staged horizontal layers and the entire surgical margin is examined microscopically during the procedure. The approach is designed to maximize complete tumor removal while conserving normal tissue and is commonly used for complex, ill‑defined, or high‑recurrence‑risk cutaneous malignancies in outpatient settings under local anesthesia.

    Definitions and Key Terms

    Mohs micrographic surgery (MMS) — definition
    DefinitionA staged, tissue‑sparing surgical technique that removes tumor layer-by-layer with microscopic examination of the entire surgical margin to ensure complete tumor removal while conserving normal tissue
    Key procedural noteRequires a single physician to act in two integrated capacities (surgeon and pathologist) for intraoperative microscopic margin evaluation
    Typical settingPerformed outpatient under local anesthesia; suitable for complex, ill‑defined, or high‑recurrence‑risk skin cancers
    Areas where tissue preservation is critical
    Anatomic sites (examples)Ears, face (especially eyes, mouth, nose, central third), feet, hands, genitalia, and perianal areas
    Additional high‑risk areas mentioned

    Policy Dates and Review History

    2023-06-22policy_reviewLatest

    Policy last reviewed (Last Review noted on document).

    2000-02-01policy_effective

    Policy effective date established.

    Policy Summary
    PayerAetna
    PolicyMohs Micrographic Surgery
    Policy CodePolicy 0383
    Change TypeNo material change
    Effective DateFeb 1, 2000
    Last ReviewJun 22, 2023
    Next Review DateApr 11, 2024
    Key ActionDocument clinical justification and supporting tumor characteristics when requesting prior authorization to demonstrate the lesion meets listed medical necessity indications.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryCPT, HCPCS and ICD-10 CodingProvider Guidance, Authorization, and DocumentationBackground and ContextDefinitions and Key TermsPolicy Dates and Review History
    Sebaceous carcinoma (SC): Observational analyses including NCDB and multi-center cohort data indicate MMS yields higher negative margin rates and improved local control versus WLE for localized sebaceous carcinoma, particularly eyelid tumors; multi-center cohort (n=360) showed lower local recurrence with MMS though metastasis and tumor-related mortality were comparable.

    MMS recommended for eyelid SC without orbital involvement to improve local recurrence control.

    Atypical fibroxanthoma (AFX): Systematic reviews indicate MMS is associated with lower recurrence rates compared with WLE; overall prognosis favorable when margins are clear.

    Pooled analyses support MMS for recurrence reduction.

    Adjunct imaging and techniques: High-resolution ultrasound demonstrated limited sensitivity (32%) and moderate specificity (88%) in one study; OCT pilot data (n=10) suggest potential to reduce MMS stages; vismodegib neoadjuvant therapy can reduce clinical tumor size but may leave residual microscopic disease detectable by MMS.

    These modalities are investigational/supportive and require further validation before routine use.

    Superficial leiomyosarcoma: Meta-analysis of case reports (48 cases) treated with MMS showed much lower recurrence rates (approx. 2.08%–6.25%) versus reported WLE recurrence rates (30%–50%), suggesting MMS may improve local control.

    Prospective trials needed for confirmation.

    Deep cutaneous fungal infections (DCFIs): Limited case-report evidence (8 patients) suggests MMS may be effective for DCFIs that have failed standard therapy, particularly when tissue preservation is important; evidence is preliminary.

    Findings require validation by well-designed studies.

    Skin substitutes for MMS wounds: Systematic review (687 patients) identified multiple skin substitutes used for MMS reconstruction but data are limited and RCTs comparing substitutes to traditional repair methods are lacking.

    Insufficient evidence to guide routine use of skin substitutes after MMS.

    Vulvar malignancies: Systematic review (29 studies, 107 cases) indicates MMS may be useful for select early vulvar cutaneous malignancies (SCC without nodal involvement, BCC, EMPD, DFSP) but NCCN vulvar cancer guideline (v1.2023) does not mention MMS as a management option; more robust studies are needed.

    Guideline absence suggests limited consensus for routine MMS in vulvar cancer.

    • Prior authorization may be requested for sebaceous carcinoma and eyelid tumors (evidence of improved local control with MMS)
    • Prior authorization may be requested for Merkel cell carcinoma (observational data show comparable OS between MMS and WLE)
    • Include tumor characteristics and rationale for MMS in justification
    Prior Authorization

    No explicit mandatory prior‑auth codes stated in this excerpt

    The policy excerpt does not specify an explicit universal prior authorization requirement or list exact codes that are subject to mandatory prior authorization; it notes that coverage of Mohs and associated codes is contingent on meeting the selection criteria and that payer rules may require authorization.

    • No explicit statement in this excerpt mandating which CPTs require prior authorization
    • Coverage is described as contingent on meeting policy indications
    Note

    Administrative guidance present but no exact prior‑auth procedures listed

    The bulletin provides administrative context and links for additional resources (Definitions, Review History, Clinical Policy Bulletin Notes) but does not enumerate specific prior authorization procedures, submission codes, or a step‑by‑step administrative workflow in this section.

    • Administrative links provided (Definitions, Review History, Clinical Policy Bulletin Notes)
    • No exact prior authorization codes or procedures specified here
    Step Therapy

    Consider standard excision for many primary BCCs; MMS preferred for recurrent BCC

    Evidence in the policy differentiates primary versus recurrent BCC: randomized trial data support that surgical excision may be sufficient for most primary facial BCCs, whereas MMS is preferred for recurrent facial BCC — consider conventional excision for many primary BCCs before selecting MMS.

    • RCT (Mosterd et al) found no significant recurrence difference for primary BCC but fewer recurrences with MMS for recurrent BCC
    • Use WLE for many primary BCCs; reserve MMS for recurrent facial BCC
    Step Therapy

    Consider less‑extensive or topical options for select lesions before MMS

    For certain lesions (e.g., lentigo maligna, small superficial penile lesions), less extensive surgical options or topical therapies may be appropriate as initial management; MMS may be selected when tissue preservation or margin control is prioritized.

    • Lentigo maligna: WLE with 5‑mm margins is standard; MMS increasingly used for larger/head‑neck or ill‑defined lesions
    • Penile cancer guidance: conservative organ‑sparing approaches (topical therapy, WLE, laser, glansectomy, or MMS) may be alternatives for select lesions
    Step Therapy

    No step‑therapy mandate in this excerpt

    The policy states that no step therapy requirements are described in this excerpt.

    Note

    No specific provider action listed

    No provider action is specified for this inventory item in the policy excerpt.

    Documentation Required

    Document that lesion meets a listed medical‑necessity indication

    Clinical documentation must demonstrate that the lesion meets one of the policy’s medical‑necessity indications (for example: anatomic site requiring tissue preservation, recurrent or incompletely excised malignant lesion, previously irradiated skin, DFSP, atypical fibroxanthoma, lesion ≥2 cm, or aggressive histology).

    • Document which listed indication is met (cite specific policy criterion)
    • Include lesion size when applicable (e.g., ≥2 cm)
    Billing Rule

    Document the physician’s dual surgeon‑and‑pathologist role when billing MMS

    If billing Mohs technique CPT codes, documentation must support that a single physician performed both the surgical and pathologic roles; if either role is delegated and reported separately by another physician, Mohs CPT codes are inappropriate.

    • Record that one physician acted in both surgeon and pathologist capacities for MMS
    • If roles delegated and billed separately, do not use Mohs CPT codes
    Documentation Required

    Suggested documentation to support medical necessity for MMS

    Include tumor site, tumor stage, prior treatments, and explicit clinical rationale for choosing MMS in the record; examples cited by the policy include eyelid or head/neck sebaceous carcinoma and other tumor‑specific rationales linked to improved margin control or tissue preservation.

    • Tumor site and stage
    • Prior treatments and attempts at excision or radiation
    • Rationale for MMS (e.g., tissue‑sparing need, evidence of improved local control for this tumor type)
    • Examples: eyelid sebaceous carcinoma, head/neck sebaceous carcinoma
    Note

    No specific documentation or prior‑authorization workflow provided here

    This part of the policy does not include a specific documentation checklist or a defined prior‑authorization workflow for providers to follow.

    Note

    Providers responsible for patient care; CPB is informational

    The Clinical Policy Bulletin is informational and does not constitute a contract; participating providers are independent contractors and are solely responsible for medical advice and treatment of members.

    • CPB is a partial description of benefits and not a coverage contract
    • Providers remain responsible for clinical care and advice to members
    Denial Risk

    OCT codes (0470T, 0471T) are listed as not covered for these indications

    Optical coherence tomography (CPT 0470T, 0471T) for margin definition is listed in the policy’s Experimental and Investigational section as not covered for indications in this CPB; claims for these OCT services for these indications may be denied.

    • CPT 0470T and 0471T are identified as not covered for indications listed in the CPB
    • OCT for margin definition of BCC before Mohs is considered investigational
    Denial Risk

    Evidence gaps (lack of RCTs) may prompt additional review or justification

    The policy notes limited high‑quality randomized evidence for some indications (e.g., peri‑ocular BCC) and states that absence of RCT data may lead to coverage scrutiny or requests for clinical justification instead of routine approval.

    • Cochrane review found no RCTs comparing MMS vs SE for peri‑ocular BCC; high‑quality trials are needed
    • Lack of RCT evidence may prompt additional review or justification requests
    Note

    No provider actions specified in this excerpt

    No specific provider actions are provided in this document excerpt for this inventory item.

    Note

    Administrative disclaimer — CPB is for benefit administration only

    The Clinical Policy Bulletin is intended to assist in benefit administration and is not an offer of coverage; policy content may be updated and is subject to change.

    External ear and tragus, mucosal lesions, nail bed and periungual areas, scalp, and temple
    Clinical relevanceThese locations are cited as indications for MMS because tissue preservation and functional/cosmetic outcomes are critical
    High-resolution ultrasound — definition & limitations
    DefinitionHigh‑resolution ultrasound is ultrasound imaging using high frequencies to assess skin tumor extent preoperatively
    Test performance (study)In one study (n=100) sensitivity = 32%, specificity = 88%, PPV = 47%, NPV = 79%
    LimitationLow sensitivity, particularly for small foci of extension (eg, infiltrative SCC, micronodular BCC); requires further refinement and cannot yet replace standard margin assessment
    Optical coherence tomography (OCT) — definition & pilot data
    DefinitionOptical coherence tomography (OCT) is a noninvasive imaging technique that can visualize basal cell carcinoma margins preoperatively
    Pilot dataIn a pilot (n=10), OCT‑guided margin mapping resulted in 8 of 10 BCCs totally excised in a single stage and reduced additional MMS stages in some cases
    Evidence caveatPilot was small; authors stated larger studies are needed to quantify whether OCT reduces stages or defect size reliably
    Vismodegib neoadjuvant therapy — definition & caution
    DefinitionVismodegib is an oral hedgehog pathway inhibitor used systemically for locally advanced or metastatic basal cell carcinoma
    Neoadjuvant effectCase reports show clinical tumor shrinkage and disappearance in some lesions after neoadjuvant vismodegib prior to MMS
    CautionResidual microscopic tumor nests were found at Mohs surgery despite clinical response, so MMS may still be required for histologic clearance
    Mohs micrographic surgery (MMS) — alternate/expanded definition
    Alternate definitionMohs micrographic surgery (MMS) is a staged excision technique with microscopic examination of entire margins to achieve complete tumor removal while preserving healthy tissue
    Indications reiteratedUsed for complex/ill‑defined skin cancers and specific tumor types (see policy medical necessity sections) where tissue‑sparing margin control is important
    Operational requirementA single physician must perform both the surgical and pathologic roles intraoperatively; separate reporting by different physicians makes MMS CPT codes inappropriate
    Definitions and review history references
    Definitions linkPolicy provides a Definitions link for detailed terminology and policy‑specific definitions
    Review history linkPolicy History and Review History links are provided with last review date 06/22/2023 and next review 04/11/2024
    Administrative noteThe Clinical Policy Bulletin includes links to review history and definitions for additional context and historical changes